(ISRG) Intuitive Surgical - Ratings and Ratios

Intuitive Surgical, Inc. is a pioneering developer of robotic-assisted, minimally invasive surgical systems and diagnostic tools. The companys flagship product, the da Vinci Surgical System, is a robotic platform that enhances surgical precision, flexibility, and control in procedures such as prostatectomies and hysterectomies, leading to improved patient outcomes and faster recovery times. Beyond surgery, Intuitive Surgical has expanded its offerings with the Ion endoluminal system, which enables minimally invasive lung biopsies, addressing a critical need in diagnostics. The company also provides a comprehensive suite of stapling, energy, and core instruments, along with progressive learning pathways to ensure effective use of its technology. Its customer support infrastructure includes installation, repair, maintenance, and 24/7 technical support, complemented by digital capabilities that enhance hospital performance through data-driven insights. Intuitive Surgical sells its products primarily through direct sales teams, focusing on capital and clinical sales. Founded in 1995 and headquartered in Sunnyvale, California, the company has established itself as a leader in the field of robotic-assisted surgery and beyond. Web URL: https://www.intuitive.com.

From a technical perspective, Intuitive Surgicals stock (NASDAQ:ISRG) is currently trading at $482.74, below its 20-day ($492.22) and 50-day ($528.23) moving averages but above its 200-day ($510.97) moving average. The Average True Range (ATR) of 24.11 indicates moderate volatility. On the fundamental side, the company has a market capitalization of $174.93 billion, with a trailing P/E of 76.05 and a forward P/E of 61.35. The price-to-book ratio is 10.64, and the price-to-sales ratio is 20.95, reflecting high valuations relative to earnings and book value. The return on equity (RoE) is 14.13%, indicating solid profitability.

3-Month Forecast: Based on the technical and fundamental data, ISRG is expected to face resistance near its 20-day and 50-day moving averages. The stock may experience sideways trading with potential downside risk due to its high valuation multiples. However, continued innovation and expansion into diagnostic markets could support long-term growth prospects.